Clinical Trial Update: Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating three transdermal doses of rotigotine for idiopathic restless legs syndrome has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Restless Legs Syndrome

Drugs mentioned

• Rotigotine (Neupro) (rotigotine)

Snippet

Sponsor: UCB Pharma | Conditions: Restless Legs Syndrome | Phase 3 | Status: COMPLETED